Efficacy and safety of TE/TEC/intensive paclitaxel neoadjuvant chemotherapy for the treatment of breast cancer.

导出 OA

翻译打印收藏纠错

作者： Yang,Liu ^[1] ; Zhaoguo,Xu ^[2] ; Zhenyong,Zhang ^[2] ; Guangfu,Wen ^[3] ; Jiaxing,Sun ^[4] ; Feng,Han ^[5]

作者单位： Department of Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110000, P.R. China. ^[1] Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110000, P.R. China. ^[2] Department of Pediatric Intensive Care Medicine, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110000, P.R. China. ^[3] Department of Ultrasonography, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110000, P.R. China. ^[4] Department of Medical Administration, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110000, P.R. China. ^[5]

关键词 adverse reactions breast cancer efficacy molecular typing neoadjuvant chemotherapy paclitaxel

DOI 10.3892/ol.2018.9658

PMID 30655846

发布时间 2020-09-30

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交